secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2026-08-06T20:32:07+00:00
Accession:  0001297184-26-000045
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar Q2 2026 revenue up 5.4% YoY to $183.9M; adjusted EPS $0.91
--------------------------------------------------------------------

- Net revenues of $183.9M for Q2 2026, up from $174.4M in Q2 2025.
- GAAP net income $30.3M ($0.67 diluted EPS) vs $31.0M ($0.64) year ago.
- Adjusted non-GAAP net income $40.8M ($0.91 diluted EPS) vs $40.9M ($0.85).
- CEO cites revenue growth, gross margin expansion, new product launches, and pipeline progress.
- Six-month 2026 GAAP net income $36.8M ($0.81) vs $56.3M ($1.15) in prior year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718426000045/0001297184-26-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718426000045/amph-20260806x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-26-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer